CEO, MDXHEALTH
WHY: Exec helming precision diagnostics company with its U.S. HQ and laboratories in Irvine. Diagnostics products aim to improve early detection of prostate cancer in a noninvasive manner and reduce the number of false negatives.
IN THE NEWS: Acquired a prostate cancer business for up to $100M from Madison, Wis.-based Exact Sciences Corp. Says the acquisition now allows the company to provide “the most comprehensive menu of advanced molecular tests for urology in prostate cancer.”
NOTABLE: Company raised around $45M in an initial public offering late last year, in part “to expand our menu in prostate cancer and other urologic diseases.”
